Last updated on May 2017

Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Schizophrenia
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other:
    Adult patients (age ≥ 18 years at the time of aripiprazole once-monthly initiation)
    Male or female
    Diagnosis of schizophrenia according to Diagnostic and Statistical Manual of Mental
    Disorders, Fifth edition (DSM-5), available at start of aripiprazole once-monthly
    treatment, and confirmed by the current investigator
    Aripiprazole once-monthly initiation (at least 1 injection) according to the clinical
    practice, at least 6 months before the inclusion and on June 1st 2015 or at a later
    date (index date)
    Aripiprazole once-monthly was the main antipsychotic at the time of treatment
    initiation
    Willingness to participate in the study; subjects must give their written consent to
    participate

You may not be eligible for this study if the following are true:

  • The patient has a psychiatric disorder other than schizophrenia as primary diagnosis
    Participation in a clinical trial during the retrospective follow-up period.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.